PredictImmune

January 24, 2020January 24, 2020

PredictImmune Partners with Cambridge Clinical to Commercialize IBD Test

News

PredictImmune has entered into a commercial partnership with Cambridge Clinical Laboratories (CCL) to provide PredictSURE IBD — its prognostic test for inflammatory bowel disease (IBD) — to clinicians in the ... Read more

November 4, 2019November 4, 2019

PredictImmune’s IBD Test Soon Will Be Available in US, Canada, Across French-speaking Europe

News

Following product launches in the United Kingdom (UK) and Ireland earlier this year, the developer of the first validated test for inflammatory bowel disease (IBD) now has reached commercialization agreements ... Read more

May 29, 2019May 29, 2019

First Prognostic Test for IBD Now Available for Patients in the UK and Ireland

News

PredictImmune‘s prognostic test for inflammatory bowel disease (IBD) is now available to clinicians and gastroenterologists in the U.K. and Ireland, the company announced. Developed in partnership with the University of Cambridge, ... Read more

April 3, 2019April 3, 2019

UK’s NICE Publishes Briefing Supporting PredictImmune Tool for Estimating IBD Flare-up Likelihood

News

The National Institute for Health and Care Excellence (NICE) supports the use of PredictImmune‘s newly launched prognostic tool, PredictSURE IBD, for estimating the likelihoood of disease flare-ups in patients with ... Read more

May 11, 2018May 11, 2018

PredictImmune Awarded £4.3M to Evaluate Ability of Prognostic Test to Guide Crohn’s Treatment

News

PredictImmune has received a £4.3 million (US$5.85 million) grant to fund a prospective clinical trial to determine if its prognostic biomarker test can help personalize treatment strategies for patients with Crohn’s ... Read more